Novartis AG (NVS) Receives Neutral Rating from J P Morgan Chase & Co

J P Morgan Chase & Co reaffirmed their neutral rating on shares of Novartis AG (NYSE:NVS) in a research report sent to investors on Tuesday morning.

Several other equities research analysts have also recently weighed in on NVS. Barclays PLC raised Novartis AG from an underweight rating to an equal weight rating in a research note on Thursday, June 22nd. Leerink Swann reissued a market perform rating and issued a $83.00 price target on shares of Novartis AG in a research note on Thursday, June 22nd. Credit Suisse Group cut Novartis AG from a neutral rating to an underperform rating and set a $82.25 price target for the company. in a research note on Wednesday, July 5th. Zacks Investment Research cut Novartis AG from a hold rating to a sell rating in a research note on Monday, July 10th. Finally, Cowen and Company set a $77.00 price target on Novartis AG and gave the company a hold rating in a research note on Tuesday, July 11th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Hold and an average target price of $84.13.

Novartis AG (NYSE:NVS) opened at 85.74 on Tuesday. The company has a market cap of $200.88 billion, a PE ratio of 31.30 and a beta of 0.73. Novartis AG has a one year low of $66.93 and a one year high of $86.90. The firm’s 50-day moving average price is $84.99 and its 200-day moving average price is $81.65.

Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.06. The company had revenue of $12.24 billion during the quarter, compared to analysts’ expectations of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The business’s quarterly revenue was down 1.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.23 earnings per share. On average, equities research analysts forecast that Novartis AG will post $4.75 earnings per share for the current fiscal year.

WARNING: “Novartis AG (NVS) Receives Neutral Rating from J P Morgan Chase & Co” was first reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://weekherald.com/2017/10/11/novartis-ag-nvs-receives-neutral-rating-from-j-p-morgan-chase-co.html.

Institutional investors have recently made changes to their positions in the stock. City Holding Co. boosted its position in shares of Novartis AG by 4.6% during the 2nd quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after purchasing an additional 54 shares in the last quarter. WFG Advisors LP boosted its position in shares of Novartis AG by 38.1% during the 2nd quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after purchasing an additional 337 shares in the last quarter. Archford Capital Strategies LLC boosted its position in shares of Novartis AG by 72.3% during the 1st quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after purchasing an additional 621 shares in the last quarter. Kernodle & Katon Asset Management Group LLC boosted its position in shares of Novartis AG by 3.4% during the 1st quarter. Kernodle & Katon Asset Management Group LLC now owns 1,488 shares of the company’s stock valued at $111,000 after purchasing an additional 49 shares in the last quarter. Finally, North Star Investment Management Corp. boosted its position in shares of Novartis AG by 1.0% during the 2nd quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after purchasing an additional 16 shares in the last quarter. Institutional investors own 10.92% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (NYSE:NVS)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply